Bionexus Gene Lab earnings were -$2.9M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest BGLC earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$543.6k, down 47.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, BGLC reported annual earnings of -$3.0M, with 86.7% growth. The next BGLC earnings date is Aug 17, 2026.
What were Bionexus Gene Lab's earnings last quarter?
Bionexus Gene Lab (NASDAQ: BGLC) reported Q1 2026 earnings per share (EPS) of -$0.23, up 35.16% year over year. Total BGLC earnings for the quarter were -$543.58 thousand. In the same quarter last year, Bionexus Gene Lab's earnings per share (EPS) was -$0.35.
The next BGLC earnings date is Aug 17, 2026. Add BGLC to your watchlist to be reminded of Bionexus Gene Lab's next earnings date.
What was BGLC's earnings growth in the past year?
As of Bionexus Gene Lab's earnings date in Q3 2026, Bionexus Gene Lab's earnings has grown year over year. BGLC earnings in the past year totalled -$2.90 million.
Is Bionexus Gene Lab profitable or losing money?
As of the last Bionexus Gene Lab earnings report, Bionexus Gene Lab is currently losing money. Bionexus Gene Lab's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$2.90 million, a 37.16% increase year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.